Sign in →

Test ID LBOR0177 IFNL3 Genotyping

Important Note

This test is rarely covered by insurance.  A Patient Acknowledgement Form for Pharmacogenomics Services is required to accompany the specimen for all Medicare and non-Medicare patients.  In addition, for Medicare patients an ABN Form should also be submitted.  In the absence of the appropriate signed form(s), the ordering provider/facility will be billed. 

For patients with Blue Cross Blue Shield of North Dakota coverage, a separate completed and signed Advance Member Notice is required to accompany the specimen.

 

Note:  Testing results may be delayed due to nation-wide supply challenges due to the COVID pandemic.  Current expected TAT is 7-10 days.  

AKA

Interferon Lambda 3 Genotyping

Additional Information

See Interferon Lambda 3 (IFNL3) Genotyping

Specimen Type/Requirements

Lavender top (EDTA) tube - Whole Blood

 

Blood samples will not be accepted for patients that have undergone an allogenic transplant (e.g. bone marrow or peripheral stem cell) OR that have a history of chronic lymphocytic leukemia (CLL).

 

Transfusion patients:  Wait at least 2 weeks after a packed cell/platelet transfusion, and at least 4 weeks after a whole blood transfusion prior to blood draw for testing.

 

Chemotherapy patients:  DNA quality may be affected if patient has received chemotherapy within the last 120 days.  Clients will be contacted to provide additional specimen if DNA quality is insufficient.

 

All specimens should be sent in the original container and should not be aliquoted to another tube. In addition, the specimen submitted should ONLY be used for this testing and should not be shared with any other testing that would also utilize this specimen type.

 

Test is not affected by hemolysis or lipemia. 

Stability/Transport

 Room Temperature    72 hours    
 Refrigerated    7 days    Preferred for transport  
 Frozen    Not Acceptable     

 

Performed Test Frequency

Monday through Friday

Methodology

Allele-specific PCR (Fluidigm)

Performing Lab

Sanford Laboratories Sioux Falls

CPT

81283

Specimen Volume

 Preferred Volume    2.0 - 4.0 mL  
 Minimum Volume    1.0 mL  

 

Useful For

  • Estimate the genetic risk of abnormal drug metabolism for drugs metabolized by IFNL3.
  • Identify genotypes shown to have a drug-gene variant relationship.

Report Available

5 - 7 days